Form 4: Oruka Therapeutics: Insider Option Grant Details

Fairmount Funds Management LLC and associated entities report the grant of stock options to a director, with vesting commencing June 2, 2026.

Summary

• Fairmount Funds Management LLC, along with Fairmount Healthcare Fund II L.P. and Fairmount Healthcare Co-Invest III L.P., have reported transactions related to Oruka Therapeutics, Inc. (ORKA).
• Peter Harwin and Tomas Kiselak, managers of Fairmount Funds Management LLC, are also listed as reporting persons.
• The primary transaction involves a stock option grant to Peter Harwin, representing a right to purchase 9,136 shares of Oruka Therapeutics' common stock.
• The exercise price for these options is $55.23 per share.
• The options vest monthly, with 1/12 of the total amount vesting each month starting from June 2, 2026, contingent upon continued service to the issuer.
• The expiration date for these options is June 1, 2036.
• Fairmount Funds Management LLC is noted as the investment manager for Fairmount Healthcare Fund II L.P. and Fairmount Healthcare Co-Invest III L.P.
• Peter Harwin and Tomas Kiselak are identified as directors and 10% owners of Oruka Therapeutics, Inc.
• Fairmount Funds Management LLC, Fairmount Healthcare Fund II L.P., and Fairmount Healthcare Co-Invest III L.P. may be considered directors by deputization due to Peter Harwin's board service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily reports on a standard stock option grant to management and related entities, with no immediate financial performance indicators or significant strategic shifts disclosed.

Positives

• Grant of stock options to a key executive/director, indicating potential future value and alignment of interests.
• Vesting schedule tied to continued service, promoting employee retention and long-term commitment.
• Clear reporting of beneficial ownership and management roles, enhancing transparency.

Negatives

• The exercise price of $55.23 per share is a significant hurdle, requiring substantial stock price appreciation for the options to be in-the-money.
• The long vesting period (starting June 2, 2026) and expiration date (June 1, 2036) suggest a long-term outlook, but also a lengthy period before potential realization of value.

Risks

• The value of the stock options is entirely dependent on the future performance and stock price of Oruka Therapeutics, Inc.
• Continued service is a condition for vesting, meaning any departure from the company before vesting completion would result in forfeiture of the unvested portion of the options.
• The disclaimer of beneficial ownership, except to the extent of pecuniary interest, may indicate complex ownership structures or arrangements that could have future implications.

Future Outlook

The filing primarily details the grant of stock options with a vesting schedule starting in June 2026 and expiring in June 2036. The future outlook for the value of these options is contingent on the company's performance and stock price appreciation over the long term.

Management Comments

• Peter Harwin, Managing Member of Fairmount Funds Management LLC, Fairmount Healthcare Fund II L.P., and Fairmount Healthcare Co-Invest III L.P., signed the filings.
• Peter Harwin also signed individually as a reporting person.
• Tomas Kiselak signed as a reporting person.

Industry Context

StockSavvy.ai notes that the reporting of stock options grants is a common practice in the biotechnology and pharmaceutical sectors, particularly for emerging companies like Oruka Therapeutics, Inc. These grants are often used to attract and retain key talent and align executive interests with shareholder value creation, especially during early-stage development or pre-commercialization phases.

Corporate Governance

Related Party Transactions

• Fairmount Funds Management LLC acts as the investment manager for Fairmount Healthcare Fund II L.P. and Fairmount Healthcare Co-Invest III L.P.
• Peter Harwin, as a manager of Fairmount Funds Management LLC, has an arrangement where he is obligated to turn over net cash or stock received from options for the benefit of a Fairmount Fund.
• Peter Harwin and Tomas Kiselak are managers of Fairmount Funds Management LLC and are also reporting persons in their individual capacities.

Stakeholder Impact

• Shareholders: The grant of options aligns management's interests with long-term shareholder value, but the exercise price and vesting schedule mean benefits are deferred and contingent on performance.
• Employees: The vesting schedule tied to continued service incentivizes key personnel to remain with the company.
• Management: Receives potential future equity compensation, contingent on performance and continued employment.

Next Steps

• Continued service by Peter Harwin to Oruka Therapeutics, Inc. to ensure vesting of stock options.
• Monitoring of Oruka Therapeutics, Inc.'s stock performance to assess the potential value of the granted options.

Key Dates

Keywords

Oruka Therapeutics, ORKA, Form 4, Stock Options, Insider Trading, Beneficial Ownership, Fairmount Funds Management, Peter Harwin, Tomas Kiselak, SEC Filing, Vesting Schedule, Director